Cancer Research Annual Meeting 2010 Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 615-621, February 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eary, J. F.
Right arrow Articles by Krohn, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eary, J. F.
Right arrow Articles by Krohn, K. A.
[Cancer Research 59, 615-621, February 1, 1999]
© 1999 American Association for Cancer Research

Clinical Investigations

2-[C-11]Thymidine Imaging of Malignant Brain Tumors1

Janet F. Eary2, David A. Mankoff, Alexander M. Spence, Mitchel S. Berger, Adam Olshen, Jeanne M. Link, Finbarr O’Sullivan and Kenneth A. Krohn

Division of Nuclear Medicine [J. F. E., D. A. M., A. O., J. M. L., F. O’S., K. A. K.], and Departments of Neurology [A. M. S.] and Neurosurgery [M. S. B.], University of Washington Medical Center, Seattle, Washington 98195-6113

Malignant brain tumors pose diagnostic and therapeutic problems. Despite the advent of new brain imaging modalities, including magnetic resonance imaging (MRI) and [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET), determination of tumor viability and response to treatment is often difficult. Blood-brain barrier disruption can be caused by tumor or nonspecific reactions to treatment, making MRI interpretation ambiguous. The high metabolic background of the normal brain and its regional variability makes it difficult to identify small or less active tumors by FDG imaging of cellular energetics. We have investigated 2-[C-11]thymidine (dThd) and PET to image the rate of brain tumor cellular proliferation. A series of 13 patients underwent closely spaced dThd PET, FDG PET, and MRI procudures, and the image results were compared by standardized visual analysis. The resulting dThd scans were qualitatively different from the other two scans in approximately 50% of the cases, which suggests that dThd provided information distinct from FDG PET and MRI. In two cases, recurrent tumor was more apparent on the dThd study than on FDG; in two other patients, tumor dThd uptake was less than FDG uptake, and these patients had slower tumor progression than the three patients with both high dThd and FDG uptake. To better characterize tumor proliferation, kinetic modeling was applied to dynamic dThd PET uptake data and metabolite-analyzed blood data in a subset of patients. Kinetic analysis was able to remove the confounding influence of [C-11]CO2, the principal labeled metabolite of 2-[C-11]dThd, and to estimate the flux of dThd incorporation into DNA. Sequential, same-day [C-11]CO2 and [C-11]dThd imaging demonstrated the ability of kinetic analysis to model both dThd and CO2 simultaneously. Images of dThd flux obtained using the model along with the mixture analysis method for pixel-by-pixel parametric imaging significantly enhanced the contrast of tumor compared with normal brain. Comparison of model estimates of dThd transport versus dThd flux was able to discern increased dThd uptake simply on the basis of blood-brain barrier disruption from retention on the basis of increased cellular proliferation. This preliminary study demonstrates the potential for imaging brain tumor cellular proliferation to provide unique information for guiding patient treatment.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Morgenroth, S. Deisenhofer, G. Glatting, F. H-G. Kunkel, C. Dinger, B. Zlatopolskiy, A. T.J. Vogg, T. Kull, and S. N. Reske
Preferential Tumor Targeting and Selective Tumor Cell Cytotoxicity of 5-[131/125I]Iodo-4'-Thio-2'-Deoxyuridine
Clin. Cancer Res., November 15, 2008; 14(22): 7311 - 7319.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Bading and A. F. Shields
Imaging of Cell Proliferation: Status and Prospects
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Muzi, A. M. Spence, F. O'Sullivan, D. A. Mankoff, J. M. Wells, J. R. Grierson, J. M. Link, and K. A. Krohn
Kinetic Analysis of 3'-Deoxy-3'-18F-Fluorothymidine in Patients with Gliomas
J. Nucl. Med., October 1, 2006; 47(10): 1612 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. H. Jacobs, A. Thomas, L. W. Kracht, H. Li, C. Dittmar, G. Garlip, N. Galldiks, J. C. Klein, J. Sobesky, R. Hilker, et al.
18F-Fluoro-L-Thymidine and 11C-Methylmethionine as Markers of Increased Transport and Proliferation in Brain Tumors
J. Nucl. Med., December 1, 2005; 46(12): 1948 - 1958.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Sun, T. J. Mangner, J. M. Collins, O. Muzik, K. Douglas, and A. F. Shields
Imaging DNA Synthesis In Vivo with 18F-FMAU and PET
J. Nucl. Med., February 1, 2005; 46(2): 292 - 296.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Muzi, D. A. Mankoff, J. R. Grierson, J. M. Wells, H. Vesselle, and K. A. Krohn
Kinetic Modeling of 3'-Deoxy-3'-Fluorothymidine in Somatic Tumors: Mathematical Studies
J. Nucl. Med., February 1, 2005; 46(2): 371 - 380.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. L. Schwartz, Y. Tamura, R. Jordan, J. R. Grierson, and K. A. Krohn
Monitoring Tumor Cell Proliferation by Targeting DNA Synthetic Processes with Thymidine and Thymidine Analogs
J. Nucl. Med., December 1, 2003; 44(12): 2027 - 2032.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
B M Seddon and P Workman
The role of functional and molecular imaging in cancer drug discovery and development
Br. J. Radiol., December 1, 2003; 76(suppl_2): S128 - S138.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D L Francis, A Freeman, D Visvikis, D C Costa, S K Luthra, M Novelli, I Taylor, and P J Ell
In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
Gut, November 1, 2003; 52(11): 1602 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Toyohara, A. Gogami, A. Hayashi, Y. Yonekura, and Y. Fujibayashi
Pharmacokinetics and Metabolism of 5-125I-Iodo-4'-Thio-2'-Deoxyuridine in Rodents
J. Nucl. Med., October 1, 2003; 44(10): 1671 - 1676.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel
Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG
J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Barthel, M. C. Cleij, D. R. Collingridge, O. C. Hutchinson, S. Osman, Q. He, S. K. Luthra, F. Brady, P. M. Price, and E. O. Aboagye
3'-Deoxy-3'-[18F]Fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography
Cancer Res., July 1, 2003; 63(13): 3791 - 3798.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, J. Grierson, M. Muzi, J. M. Pugsley, R. A. Schmidt, P. Rabinowitz, L. M. Peterson, E. Vallieres, and D. E. Wood
In Vivo Validation of 3'deoxy-3'-[18F]fluorothymidine ([18F]FLT) as a Proliferation Imaging Tracer in Humans: Correlation of [18F]FLT Uptake by Positron Emission Tomography with Ki-67 Immunohistochemistry and Flow Cytometry in Human Lung Tumors
Clin. Cancer Res., November 1, 2002; 8(11): 3315 - 3323.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Wells, R. N. Gunn, M. Alison, C. Steel, M. Golding, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price
Assessment of Proliferation in Vivo Using 2-[11C]Thymidine Positron Emission Tomography in Advanced Intra-abdominal Malignancies
Cancer Res., October 15, 2002; 62(20): 5698 - 5702.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. S. Rasey, J. R. Grierson, L. W. Wiens, P. D. Kolb, and J. L. Schwartz
Validation of FLT Uptake as a Measure of Thymidine Kinase-1 Activity in A549 Carcinoma Cells
J. Nucl. Med., September 1, 2002; 43(9): 1210 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. M. Dupertuis, M. Vazquez, J.-P. Mach, N. De Tribolet, C. Pichard, D. O. Slosman, and F. Buchegger
Fluorodeoxyuridine Improves Imaging of Human Glioblastoma Xenografts with Radiolabeled Iododeoxyuridine
Cancer Res., November 1, 2001; 61(21): 7971 - 7977.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. Seitz, M. Wagner, A. T. Vogg, G. Glatting, B. Neumaier, F. R. Greten, R. M. Schmid, and S. N. Reske
In Vivo Evaluation of 5-[18F]Fluoro-2'-deoxyuridine as Tracer for Positron Emission Tomography in a Murine Pancreatic Cancer Model
Cancer Res., May 1, 2001; 61(10): 3853 - 3857.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
R. G. Blasberg, U. Roelcke, R. Weinreich, B. Beattie, K. von Ammon, Y. Yonekawa, H. Landolt, I. Guenther, N. E. A. Crompton, P. Vontobel, et al.
Imaging Brain Tumor Proliferative Activity with [124I]Iododeoxyuridine
Cancer Res., February 1, 2000; 60(3): 624 - 635.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.